论文部分内容阅读
目的观察瑞舒伐他汀对血脂正常的原发性高血压患者心踝指数及踝臂指数的影响。方法不伴高血脂症的原发性高血压患者130例随机分为对照组(n=63)和治疗组(n=67,瑞舒伐他汀10mg,每晚1次),疗程均为3月。入选前所有患者经服用降压药物后血压控制在140/90mmHg以下至少4周。观察心踝血管指数(CAVI)、踝臂指数、血压、血脂在治疗前后的变化。结果治疗3月末时,两组治疗前后及组间血压变化无明显差异。瑞舒伐他汀治疗组治疗3月后总胆固醇、LDL-C较基础值分别降低(1.7±1.0)和(0.7±0.4)mmol/L,与对照组[(-0.10±0.06)、(-0.06±0.03)mmol/L]比较,差异均有统计学意义(均P<0.05)。瑞舒伐他汀组治疗3月后CAVI值降低0.58±0.12,踝臂指数值升高0.18±0.10,与对照组(0.12±0.10、-0.06±0.04)比较,差异均有统计学意义(均P<0.05)。对照组治疗前后血脂各项指标、CAVI及踝臂指数的差异均无统计学意义(P>0.05)。Pearson相关分析及多元逐步回归分析显示,CAVI与年龄、收缩压、总胆固醇、LDL-C呈正相关;踝臂指数与年龄、收缩压、总胆固醇、LDL-C呈负相关(均P<0.05)。结论瑞舒伐他汀可改善血脂正常的原发性高血压患者的动脉弹性功能。
Objective To observe the effect of rosuvastatin on the ankle index and ankle brachial index in patients with essential hypertension with essential hypertension. Methods 130 patients with essential hypertension without hyperlipidemia were randomly divided into control group (n = 63) and treatment group (n = 67, rosuvastatin 10 mg, once per night). The course of treatment was March . All patients undergoing antihypertensives were given BP control at 140/90 mmHg for at least 4 weeks prior to enrollment. The changes of heart and ankle vascular index (CAVI), ankle brachial index, blood pressure and blood lipids were observed before and after treatment. Results at the end of 3 treatment, two groups before and after treatment and no significant difference in blood pressure between groups. After 3 months of treatment with rosuvastatin, total cholesterol was decreased by (1.7 ± 1.0) and (0.7 ± 0.4) mmol / L, respectively, compared with baseline (-0.10 ± 0.06, -0.06 ± 0.03) mmol / L], the differences were statistically significant (all P <0.05). In the rosuvastatin group, the CAVI decreased by 0.58 ± 0.12 and the ankle-brachial index increased by 0.18 ± 0.10 after 3 months of treatment, with significant differences compared with the control group (0.12 ± 0.10, -0.06 ± 0.04) <0.05). There was no significant difference in each index of blood lipid, CAVI and ankle-brachial index in the control group before and after treatment (P> 0.05). Pearson correlation analysis and multiple stepwise regression analysis showed that CAVI was positively correlated with age, systolic blood pressure, total cholesterol and LDL-C. Ankle-brachial index was negatively correlated with age, systolic blood pressure, total cholesterol and LDL-C (all P <0.05) . Conclusion Rosuvastatin can improve arterial elasticity in patients with essential hypertension with normal blood lipids.